Oprean Cristina Marinela, Badau Larisa Maria, Segarceanu Nusa Alina, Ciocoiu Andrei Dorin, Rivis Ioana Alexandra, Vornicu Vlad Norin, Hoinoiu Teodora, Grujic Daciana, Bredicean Cristina, Dema Alis
Morphopathology Department, "Victor Babeş" University of Medicine and Pharmacy, Eftimie Murgu Sq. Nr.2, 300041 Timişoara, Romania.
Department of Oncology-ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania.
Diagnostics (Basel). 2021 Apr 19;11(4):725. doi: 10.3390/diagnostics11040725.
The orbit represents an unusual metastases site for patients diagnosed with cancer, however, breast cancer is the main cause of metastases at this level. These orbital metastases were discovered in patients with a history of breast cancer as unique or synchronous lesions. We present a rare case of a unique retroocular metastasis as the first initial symptom of a tubulo-lobular mammary carcinoma in a postmenopausal woman. A 57-year-old patient complains of diplopia, diminishing visual acuity, orbital tenderness, slight exophthalmia and ptosis of the left eyelid, with insidious onset. Clinical examination and subsequent investigations revealed a left breast cancer cT2 cN1 pM1 stage IV. Breast conserving surgery was performed on the left breast. Pathological examination with immunohistochemistry staining established the complete diagnostic: pT2pN3aM1 Stage IV breast cancer, luminal B subtype. After two years from the initial breast cancer diagnosis, the patient was diagnosed by the psychiatrist with a depressive disorder and was treated accordingly. Orbital metastases are usually discovered in known breast cancer patients and they are found in the context of a multi-system end-stage disease. Most reports cite that up to 25% of the total orbital metastases cases are discovered before the diagnosis of the primary tumor, as our case did. MRI is the gold standard for evaluating orbital tumors. The ILC histological subtype metastasizes in the orbitals more frequently than invasive ductal carcinoma. The prognosis of patients with orbital metastases is poor. The median survival after diagnosis of orbital metastases from a breast cancer primary is ranging from 22 to 31 months. Overall survival of our patient was 56 months, longer than the median survival reported in literature. Orbital metastases must be taken into account when patients accuse ophthalmologic symptoms even in the absence of a personal history of cancer. Objective examination of every patient that incriminates these types of symptoms is essential, and breast palpation must be made in every clinical setting. Orbital biopsy is necessary for the confirmation of the diagnosis and for an adequate treatment. Although recommendations for management of orbital metastases are controversial, it appears that multidisciplinary treatment of both metastases and primary cancer improves overall survival.
眼眶是癌症患者不常见的转移部位,不过,乳腺癌是该部位转移的主要原因。这些眼眶转移瘤在有乳腺癌病史的患者中被发现,表现为单发或同时出现的病灶。我们报告一例罕见病例,一名绝经后女性以罕见的眼球后转移瘤作为小叶型乳腺癌的首发症状。一名57岁患者主诉复视、视力下降、眼眶压痛、轻度眼球突出及左眼睑下垂,起病隐匿。临床检查及后续检查显示为左乳癌cT2 cN1 pM1 四期。对左侧乳房实施了保乳手术。免疫组化染色的病理检查确立了完整诊断:pT2pN3aM1 四期乳腺癌,管腔B亚型。自最初诊断乳腺癌两年后,患者被精神科医生诊断为抑郁症并接受相应治疗。眼眶转移瘤通常在已知乳腺癌患者中被发现,且多见于多系统终末期疾病。大多数报告指出,高达25%的眼眶转移瘤病例在原发性肿瘤诊断之前就已被发现,我们的病例就是如此。磁共振成像(MRI)是评估眼眶肿瘤的金标准。小叶原位癌组织学亚型比浸润性导管癌更易转移至眼眶。眼眶转移瘤患者的预后较差。乳腺癌原发灶眼眶转移瘤诊断后的中位生存期为22至31个月。我们患者的总生存期为56个月,长于文献报道的中位生存期。即使患者没有癌症个人史,当他们出现眼科症状时,也必须考虑眼眶转移瘤的可能。对每例出现此类症状的患者进行客观检查至关重要,且在每种临床情况下都必须进行乳房触诊。眼眶活检对于确诊和适当治疗是必要的。尽管对于眼眶转移瘤的治疗建议存在争议,但多学科治疗转移瘤和原发性癌症似乎可提高总生存期。